

Barriers to implement rapid HIV testing (RHT) in French General Practitioners' offices Outcomes from DEPIVIH study

<u>R. Gauthier²</u>, A. Wajsbrot¹, S. Bouée¹, J.M. Livrozet¹, F. Prevoteau du Clary¹, S. Heber Suffrin¹, O. Taulera¹, C. Majerholc¹, C. Compagnon¹, J.M. Peter¹, J.P. Aubert¹

1: GERVIH, 59 rue du ruisseau, 75018 Paris, France

2: Département de médecine générale, Université Paris Diderot-Paris 7, 16 rue Henri Huchard, 75018 Paris, France



DEPIVIH study : grant support from Gilead and Vikia RHT offered by bioMerieux No conflicts of interest





Background

- In France:
 - HIV screening: 5 million tests performed / 6,700 new HIV infections diagnosed per year
 - More than 60,000 GPs in private practices
 - ¾ of the tests made after a private physician prescription
 - Around 50,000 people anaware of their seropositive status
 - 30% of new diagnosis are late presentation of HIV infection (CD4 cell counts < 200/mm³ or AIDS)





Background

- Last national HIV testing guidelines updated in 2008 recommend the development of routine testing and alternive HIV counseling and testing. <u>http://www.has-sante.fr</u>
- Based on many studies, mostly settled in the USA, rapid HIV tests are now encouraged in every primary care venue.
- Little is known about feasibility of RHT in physicians' private offices in Europe.





DEPIVIH-Objectives

• Primary endpoint

- To determine feasibility and acceptability of a new rapid HIV test based screening procedure in French physicians' private offices (E-poster N° CDD077 – IAS 2011)
- Secondary endpoints
 - To identify difficulties associated with this new procedure
 - To measure patients' satisfaction





DEPIVIH-Methods

- Prospective interventional study led in French physicians' private offices during 30 working days between June and October 2010
- Investigators:
 - Physicians affiliated to HIV healthcare networks
 - Practising in private offices (ie non working in STD/GUM clinic)
 - Trained to use the RHT
- Population:
 - Adult patients visiting their physician, aged > 18 and covered by medical insurance
 - Exclusion criteria: impossibility to complete the consent form





DEPIVIH-Methods

 Patients waiting for their physician were informed about the possibility of having RHT during their consultation.



- RHT was performed following spontaneaous patient request or physician recommendation.
- VIKIA[®] HIV 1/2 with finger-stick whole blood was used.





VIKIA[®] HIV ¹/₂ (bioMérieux)




1/ Capillary puncture with microlancet after hand warming



2/ Whole blood 75µL collection using a capillary tube



3/ Immediate deposit of the blood sample in the well







DEPIVIH-Methods

- Concerning inconvenience and barriers to RHT use :
 - Real time recorded : technical difficulties met during testing procedure.
 - Post-study queries :
 - Global satisfaction according to physicians with rapid RHT
 - Main barriers identified for a routine use





DEPIVIH- Demography

- 95 physicians recruited:
 - 84 GPs, 6 dermatologists, 1 gynecologist
 - 62 enrolled at least one patient
 - 23 (24%) reached the goal of 10 RHT done
- 383 patients included:

 187 (48.8%) female, 196 (51.2%) male
 Mean age 36.2 years old [18-86]
- 382 RHT accepted and completed





DEPIVIH - Main results

Feasibility at physicians' office : 1.5%

 $Feasibility = \frac{n \text{ patients tested}}{n \text{ patients with unknown serostatus}} = \frac{5.6}{371} = 0.015$

n: mean number

Outpatient acceptance rate: 99.7%

Acceptability =	N patients accepting RHT	382	- 0.997
	N patients included	$=\frac{1}{383}=0.9$	- 0.777

N: number





DEPIVIH-Testing data

Population meeting inclusion	on criteria	N= 383	
Prior history of HIV screening	Yes	299	(78.1%)
	No	84	(21.9%)
Last test (mean): 2.9 years			
Reason for rapid HIV testing	Patient's request	244	(64.7%)
(N= 377)	Physician's recommendation	133	(35.3%)
RHT accepted and done	Yes	382	(99.7%)
	No	1	(0.3%)
Population tested		N= 382	
Test result (N= 378)	Negative	348	(92.1%)
	Invalid	30	(7.9%)
Difficulty during the testing	Yes	157	(41.9%)
procedure (N = 375)	No	218	(58.1%)





Details of difficulties encountered

Physician had at least one problem with achieving the test	N= 157	
Blood sampling	143	(91.7%)
Problem with handling test kit	2	(1.3%)
Uninterpretable result	10	(6.4%)
Other difficulties	21	(13.5%)

- Other difficulties:
 - Insufficient quantity of blood withdrawal using the microlancet (3),
 - Air bubble in the capillary tube or the well (6),
 - Handling the capillary tube (5),
 - Blood coagulation in the tube (1),
 - Inability to draw blood resulting in test failure (2),
 - Lack of test reaction (3),
 - Insuficient of time to complete test (1).





Invalid test results

		Test result	
		Invalid N = 30	Negative N = 342
Difficulties during testing procedure	Yes	27 (90.0%)	129 (37.7%)
	No	3 (10.0%)	213 (62.3%)

- Characteristics of physicians obtaining invalid results:
 - 19 physicians, sex ratio: 1, mean age 47.1 years old
 - 12 (66.7%) attended the training session in Paris
 - mean number of RHT performed: 6.2 [1-11]
 - mean number of invalid test results: 1.6 [1-4]





Barriers to implementation of HIV rapid testing identified by the investigators

Investigators who filled post-study questionnaire		N= 72	
What obstacles did you encounter with the RHT procedure?	Blood sampling issue	31	(43.1%)
	Time constraint	9	(12.5%)
	Patient's refusal	3	(4.1%)
	Need to test for more than one STI	2	(2.8%)
	Doubt on test result fiability	2	(2.8%)
	Other	4	(5.5%)
	None	21	(29.2%)
Would you continue to use RHT in your daily practice? (N= 69)	Yes	41	(59.4%)
	No	28	(40.6%)





Conclusion

- First study evaluating feasibility of rapid HIV testing in primary care private practice in France.
- Rapid screening with RHT is new in France = training needed to assure quality control.
- Principle barriers identified to implementation of RHT:
 - Blood sampling issues,
 - Time constraints.
- Need for « ready to use » RHT:
 - Improve/simplify sampling method,
 - Convenient packaging.





Acknowledgements

• DEPIVIH investigators:

- AVIGNON: M. Cadart, D. Depieds, B. Muscat, J. Peyre, G. Pichancourt, P. Regard, J.L. Vidal, A. Wajsbrot
- LYON: S. Bereni, E. Carbonnel, I. Chevalier, N. Corsini, P. Chiarello, V. Gueripel, J.J. Jourdain, A. Juppet, J.F. Plaskowski, G. Retornaz,
- MARSEILLE: K. Bartolo, C. Compagnon, C. Larpin, F. Laurent, A. Madrid, M. Monod, N. Petit, A. Rieu, M.L. de Severac, M. Sordage, D. Sperandeo, F. Tollinchi
- MULHOUSE: C. Beck, J.M. Dietrich, J.M. Meyer, C. Pelissier, I. Willemain
- PARIS: L. Arditti, J.P. Aubert, D. Avramov, E. Becel, V. Bergerol, D. Bloit, G. Castanedo, A. Catusse, E. Cazenave, C. Chaumie, J.L. Cherabieh, M. Denantes, P. Denoyelle, A. Di Pumpo, A. Eddi, N. Gauffier, J. Gelly, F. Ghirardelli, S. Klayer, J.J. Krief, M. Lalande, N. Lazimi, J.L. Leymarie, C. Majerholc, T. Mazars, Y. Melchior, D. Menard, E. de sa Moreira, M. Nougairède, N. Pillon, C. Plaussu, I. Poirier-Langlois, A. Samoun, P. Santana, B. Selle, J. Yacoubovitch, J. Zurbach,
- PAU: S. Beroud, F. Etchebar, N. Hadj, C. Leborgne, E. Lebouteiller, C. Louet, L. Magot, M. Poli, K. Tellier
- TOULOUSE: M. Adam, P. Allenou, C. Aquilina, C. Brustet, B. Chicoulaa, M. Deleris,
 F. Fourcade, C. Hambourg, A. Laforgue, F. Lucas, M. Palaze, F. Prevoteau du Clary, S. Raluy, P. Razongles